Publications by authors named "Katherine Crisafi"
Article Synopsis
- The AMP trials showed that the broadly neutralizing antibody (bnAb) VRC01 can block infections from certain HIV-1 strains, proving that this approach could work for prevention.
- There is potential for using combinations of different bnAbs, like PGT121 and PGDM1400, along with longer-lasting variants, to enhance immunity against HIV-1.
- A new multiplexed microsphere-based assay has been developed to accurately measure the levels of infused bnAbs in human serum, which is crucial for determining effective doses for HIV prevention and therapy.
Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection in infants, immunocompromised patients, and the elderly. The RSV fusion (F) protein mediates fusion of the viral envelope with the target cell membrane during virus entry and is a primary target for antiviral drug and vaccine development. The F protein contains two heptad repeat regions, HR1 and HR2.
View Article and Find Full Text PDF